INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,346,237 | +38.7% | 126,550 | -17.2% | 0.01% | +50.0% |
| Q2 2023 | $1,691,074 | -13.3% | 152,900 | +5.2% | 0.01% | -27.3% |
| Q1 2023 | $1,951,258 | +10.9% | 145,291 | +2.2% | 0.01% | +10.0% |
| Q4 2022 | $1,759,299 | -7.4% | 142,223 | +4.4% | 0.01% | -16.7% |
| Q3 2022 | $1,900,000 | +40.3% | 136,193 | +38.9% | 0.01% | +50.0% |
| Q2 2022 | $1,354,000 | -22.1% | 98,036 | -8.2% | 0.01% | -11.1% |
| Q1 2022 | $1,738,000 | -9.3% | 106,843 | -9.2% | 0.01% | 0.0% |
| Q4 2021 | $1,916,000 | +9.2% | 117,629 | -0.4% | 0.01% | 0.0% |
| Q3 2021 | $1,754,000 | -26.8% | 118,095 | -1.6% | 0.01% | -25.0% |
| Q2 2021 | $2,396,000 | -6.5% | 119,996 | +8.1% | 0.01% | -14.3% |
| Q1 2021 | $2,563,000 | +282.0% | 111,045 | +2482.4% | 0.01% | +180.0% |
| Q4 2014 | $671,000 | – | 4,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |